


Curriculum vitae: Hans-Peter Marti



ROLE IN PROJECT

Supervisor/Project Leader

PERSONAL INFORMATION

MARTI, Hans-Peter

Date of birth: 25.03.1956, M, Zurich, Switzerland

ORCID, researcher ID: <https://orcid.org/0000-0002-6331-5902>

URL for personal UiB web site: <http://www.uib.no/en/persons/Hans-Peter.Marti>

EDUCATION

- 2011 Fellow of the American Society of Nephrology (FASN).
- 2009-2011 Management in Health Care (5 modules), Univ. of St. Gallen (HSG), Switzerland.
- 1992 FMH Nephrologie (Board certification in Nephrology), Switzerland.
- 1989 FMH Innere Medizin (Board certification in Internal Medicine), Switzerland.
- 1984 ECFMG examination (USA).
- 1982 Dr. med., University of Basel, date: 20.12.1982.
- 1976-1982 Medical School, Univ. of Basel, Switzerl. and Univ. of Otago, Dunedin, New Zealand.

CURRENT AND PREVIOUS POSITIONS

- Since 2013 Full Professor of Nephrology, University of Bergen (UiB), and Consultant, Nephrology Section, Dept. of Medicine, Haukeland University Hospital, Bergen, Norway.
- 2011-2013 Director/Chief Physician, Dept. of Medicine, Bürgerspital, Solothurn, Switzerland.
- 2005-2011 Consultant/Deputy Director, Nephrology & Hypertension, University Hospital, Bern.
- 2010 Senior Researcher and Consultant, Nephrology Section, Department of Medicine, Dunedin Hospital, University of Otago, New Zealand (6 months sabbatical).
- 2004-2005 Consultant and Deputy Director, Nephrology, University Hospital Zurich, Zurich.
- 2003-2004 Senior research position, INSERM U702, Hôpital Tenon, Paris, France.
Funding: Scholarship from INSERM (poste orange), France (12 months).
- 2003 Associate Professorship, University of Bern, Bern, Switzerland.
- 1992-2003 Senior Registrar/Consultant at University Hospitals of Zurich and Bern, Switzerland.
- 1989 Assistant Professorship (Habilitation), University of Bern, Bern, Switzerland.
- 1982-1989 Junior Doctor (House Surgeon/Registrar) in New Zealand (2 years) and Switzerland.

MAIN SUPERVISION

1992-2016 Number of Postdocs: 4; PhD: 15 (incl. 3 MD theses in Bern); Master Students: 5

Main Supervision in the past

- 2016-2019 Lea Landolt, PhD, Dept. of Clinical Medicine, University of Bergen (UiB)
- 2015-2019 Øystein S. Eikrem, PhD, Dept. of Clinical Medicine, University of Bergen (UiB)
- 2014-2017 Rannveig Skrunes, PhD, UiB, Bergen; *veiledet together with C. Tøndel*
- 2011-2013 Aikaterini Anagnostopoulou, PhD, Postdoc, Faculty of Medicine, Univ. of Bern
- 2010-2012 Maria Otth, MD, Faculty of Medicine, University of Bern, Bern
- 2010-2011 Rödder Silke: PhD, Postdoc, Faculty of Medicine, University of Bern
- 2009-2010 Rödder Silke: PhD, Faculty of Medicine, University of Bern
- 2007-2010 Suana Angela: PhD, Faculty of Medicine, University of Bern
- 2003-2006 Tuffin Gérald: PhD, Faculty of Medicine, University of Bern
- 2002-2006 Berthier Céline: PhD, Faculty of Medicine, University of Bern
- 2000-2004 Lods Nadège: PhD, Faculty of Medicine, University of Bern
- 1997-2000 Daniel Catherine: PhD, Faculty of Medicine, University of Bern
- 1996-1999 Ziswiler Ruth: PhD, Faculty of Medicine, University of Bern
- 1994-1997 Niggli Karin F.: PhD, Faculty of Medicine, University of Bern
- 1994-1996 Küng Marc M.: MD, Faculty of Medicine, University of Bern
- 1992-1995 Lukes-Marx Manuela P.: MD, Faculty of Medicine, University of Bern

Main Supervision ongoing

2019-2023	Ole Petter Nordbø, PhD student, Dept. of Clinical Medicine, UiB, Bergen
2019-2022	Philipp Strauss, PhD student, Dept. of Clinical Medicine, UiB, Bergen
2018-2022	August Hoel, PhD student, Dept. of Clinical Medicine, UiB, Bergen
2017-2021	Hassan Elsaid, PhD student, Dept. of Clinical Medicine, UiB, Bergen
2017-2020	Janka Babickova, PhD, Postdoc, UiB, Bergen
2015-2021	Camilla Tøndel, PhD, Postdoc, Helse Bergen, Bergen
2016-2019	Forskerlinje students (FL): Evan Koch, Sigrid Nakken, and Bjornar Lillefosse.

COMMISSIONS OF TRUST & INSTITUTIONAL RESPONSIBILITIES

Since 2019	President of the Norwegian Society of Hypertension (<i>Norsk Hypertensjonsforening</i>).
Since 2019	Leader of Nephrology and Urology Section at University of Bergen, Norway.
Since 2019	International Society of Nephrology (ISN): Member of the ISN Educational Ambassadors Program Committee.
2019 & 2016	Reviewer (opponent) of PhD and MD theses, University Paris VI, Paris, France.
2018	Reviewer for Wallenberg Scholars, Karolinska Institutet, Stockholm, Sweden.
Since 2015	Helse Sør-Øst RHF, Oslo, Norway: Appointed member of the grant review committee «Vurderingskomite - Kategori - Klinisk somatisk», Forskningsmidler.
Since 2014	International Society of Nephrology: Member of Regional Board Western Europe.
Since 2013	Leader of the Renal Research Group at the University of Bergen, Norway.
2008	Swiss Academy of Medical Sciences (SAMS), medical ethical guidelines and recommendations: "Live donation of solid organs"; member of the committee.
Since 2007	Swiss Transplant Cohort Study: Scientific Committee.
2007-2011	Director, Transplant Centre, University Hospital of Bern, Bern, Switzerland, and co-director/founding member of the Clinical Trials Unit (CTU) in Bern.
2007-2010	Swiss Transplant Cohort Study (STCS): Board of Representatives.
2007-2009	Medical Director, Swisstransplant, Bern, Switzerland.
2005	Foreign Expert for the Evaluation of the INSERM U507, Hôpital Necker, F-Paris.
2003-2005	President of the Swiss Society of Nephrology (SSN).
Since 2000	Lecturer and member of planning group nephrology, 2 nd year, University of Bern.

AWARDS AND HONORS

2016	Fulbright Scholarship for Miroslav Sekulic, University of Minnesota, USA, to join my research laboratory in Bergen, Norway.
2013	Honorary Doctorate (Dr. h.c.), Medical University of Varna, Varna, Bulgaria. <i>Reason: Co-leader of a program to introduce kidney transplantation in Varna.</i>
2007	Pfizer Research-Prize, in "Basic Research in Nephrology and Urology".
2000	Heinrich-Wirz Research Prize, Swiss Society of Nephrology.
1989-1992	Research Fellowship, David H. Lovett, Nephrology-VAMC, University of California at San Francisco (UCSF), San Francisco, USA. <i>Funding: Scholarship from the Swiss National Science Foundation (SNF).</i>

TEACHING RESEARCH ("DECISION MAKING")

- The first study on „Judgment Analysis“, which I conducted as principle investigator, investigated the intra-individual consistency of nephrologists when assessing patients with renal disease: Pfister M, et al. *Am J Kidney Dis*, 34(3):569-575, 1999.
- In the second study on "Decision Analysis" for kidney transplant patients, I participated as co-author: Girardi V, et al. *Kidney Int*, 66(1):275-383, 2004.

CAREER BREAKS

2005	Death of my wife Kathrin and my elder son Michael in a traffic accident on 17th April 2005. Time off work: 3 months thereafter. No other period of more than two months without work in my professional career.
------	---

GRANTS

Competitive research grants from 1994 to 2024 in Euro (€)

Institutions in Switzerland, France and Norway	Time / Period	Amount (€)
Novartis Foundation for Medical-Biological Research	2010	56.000
Swiss National Science Foundation (SNSF): as Principle Investigator and as the only applicant; <i>uninterrupted funding</i>	1994 - 2010	1.065.000
Swiss National Science Foundation (SNSF): CTU Bern, Co-Applicant	2007 - 2010	980.000
Swiss National Science Foundation (SNSF): STCS as Co-Applicant	2011 - 2014	3.425.000
France (INSERM and EFG)	2003 - 2004	70.000
Kurt and Senta Herrmann-Foundation (Vaduz, Liechtenstein)	1996 and 1997	72.500
Heinrich-Wirz-Prize, Swiss Society of Nephrology (SSN)	2000	18.500
Pfizer Research Prize in "Basic Research in Nephrology and Urology"	2007	46.500
"3K-Project" Univ. Hospital of Bern (project on quality assessment)	1996 - 1997	37.250
Additional funding: Norway (Shire, Amicus and Genzyme; UiB)	2013 - 2020	808.330
Helse Vest 2017 "open project" support on renal cell carcinoma	2017 - 2020	410.000
Helse Vest 2018 "open project" support on Fabry nephropathy	2018- 2021	462.000
Helse Vest 2019, Strategic Funding: «Hypertensive Nephropathy»	2020- 2024	2.100.000
Total amount		9.551.580

Total of competitive and non-competitive research grants from 1994 to 2024 in Euro (€)

Type of research grants	Time / Period	Amount (€)
Competitive funding from as described above	1994 - 2024	9.551.580
Additional non-competitive funding: Switzerland	1995 - 2015	510.000
Additional non-competitive funding: Norway (e.g. Genzyme, Alexion)	1995 - 2020	85.000
Total amount		10.146.580

LIST OF SCIENTIFIC PUBLICATIONS: 2014-2020

Publications as listed in "Pubmed": n=117. **H-Index: 27 (Web of Science) and 30 (Scopus).**

Original Work (as listed in PubMed)

- Hirt-Minkowski P, **Marti HP**, Hönger G, Grandgirard D, Leib SL, Amico P, Schaub S. Correlation of serum and urinary matrix metalloproteases/tissue inhibitors of metalloproteases with subclinical allograft fibrosis in renal transplantation. *Transpl Immunol*, 30(1):1-6, 2014.
- Marti HP**, Fuscoe JC, Kwekel JC, Anagnostopoulou A, Scherer A. Metzincins and related genes in experimental renal ageing: towards a unifying fibrosis classifier across species. *Nephrol Dial Transplant*. 29(6): 1177-85, 2014.
- Vethe H, Finne K, Skogstrand T, Vaudel M, Vikse BE, Hultström M, Placier S, Scherer A, Tenstad O, **Marti HP**. Distinct Protein Signature of Hypertension-induced Damage in the Renal Proteome of Two-Kidney-One-Clip (2K1C) Rat Model. *J Hypertens*, 33(1):126-35, 2015.
- Wójtowicz A, Lecompte TD, Bibert S, Manuel O, Rüeger S, Berger C, Boggian K, Cusini A, Garzoni C, Hirsch H, Khanna N, Mueller NJ, Meylan PR, Pascual M, van Delden C, Bochud PY, Swiss Transplant Cohort Study STCS (**Marti HP** listed here). PTX3 Polymorphisms and Invasive Mold Infections after Solid Organ Transplantation. *Clin Infect Dis*, Dec 15;61(12):1894-5, 2015.
- Quteineh L, Bochud PY, Golshayan D, Crettol S, Venetz JP, Manuel O, Kutalik Z, Treyer A, Lehmann R, Mueller NJ, Binet I, van Delden C, Steiger J, Mohacsi P, Dufour JF, Soccac PM, Pascual M, Eap CB; and The Swiss Transplant Cohort Study (**Marti HP** listed here). CRT2 polymorphism as a risk factor for the incidence of metabolic syndrome in patients with solid organ transplantation. *Pharmacogenomics J*, Dec 8. doi: 10.1038, 2015.
- Finne K, **Marti HP**, Leh S, Skogstrand T, Vethe H, Tenstad O, Berven FS, Scherer A, Vikse BE. Proteomic Analysis of Minimally Damaged Renal Tubular Tissue from Two-Kidney-One-Clip Hypertensive Rats Demonstrates Extensive Changes Compared to Tissue from Controls. *Nephron*, 132(1):70-80, 2016.

7. Eikrem O, Beisland Ch, Hjelle K, Flatberg A, Scherer A, Landolt L, Skogstrand T, Leh S, Beisvag V, **Marti HP**. Transcriptome Sequencing (RNAseq) enables utilization of Formalin-Fixed, Paraffin-Embedded Biopsies with Clear Cell Renal Cell Carcinoma for Exploration of Disease Biology and Biomarker Development. *PLOS ONE*, Feb 22;11(2):e0149743, doi: 10.1371, 2016.
8. Golshayan D, Wójtowicz A, Bibert S, Pyndiah N, Manuel O, Binet I, Buhler LH, Huynh-Do U, Mueller T, Steiger J, Pascual M, Meylan P, Bochud PY; Swiss Transplant Cohort Study (**Marti H.P.** listed here). Polymorphisms in the lectin pathway of complement activation influence the incidence of acute rejection and graft outcome after kidney transplantation. *Kidney Int*, 89(4):927-38, 2016.
9. Landolt L, **Marti HP**, Beisland C, Flatberg A, Eikrem O. RNA Extraction for RNA Sequencing of Archival Renal Tissues. *Scand J Clin Lab Invest*. 13:1-9, 2016.
10. Ruggaio P, Svarstad E, Leh S, **Marti H.P**, Reisæter A, Vikse B.E. Low Birth Weight and Risk of Progression to End Stage Renal Disease in IgA Nephropathy - A Retrospective Registry-Based Cohort Study. *PLOS One*, Apr 19;11(4):e0153819. doi: 10.1371, 2016.
11. Héquet D, Kralidis G, Carrel T, Cusini A, Garzoni C, Hullin R, Meylan PR, Mohacsi P, Mueller NJ, Ruschitzka F, Tozzi P, van Delden C, Weisser M, Wilhelm MJ, Pascual M, Manuel O; Swiss Transplant Cohort Study (**Marti H.P.** listed here). Ventricular assist devices as bridge to heart transplantation: impact on post-transplant infections. *BMC Infect Dis*. Jul 8;16:321. doi: 10.1186/s12879-016-1658-0, 2016.
12. Eikrem O, Strauss Ph, Beisland Ch, Scherer A, Landolt L, Flatberg A, Leh S, Beisvag V, Hjelle K, Shresta A, **Marti HP**. Development and Confirmation of Potential Gene Classifiers of Human Clear Cell Renal Cell Carcinoma using Next-Generation sequencing (RNAseq). *Scand J Urol*, 50(6):452-462, 2016.
13. Skrunes R, Svarstad E, Reisæter A, **Marti HP**, Vikse BE. End stage renal disease predicts increased risk of death in first-degree relatives in the Norwegian population *PLOS One*, Nov. 9;11(11):e0165026, 2016.
14. Mauthner O, Claes V, Walston J, Engberg S, Binet I, Dickenmann M, et al; Swiss Transplant Cohort Study (STCS, **Marti H.P.** listed here). Exploring frailty and mild cognitive impairment in kidney transplantation to predict biomedical, psychosocial and health cost outcomes (GERAS): protocol of a nationwide prospective cohort study. *J Adv Nurs*. Oct 12. doi: 10.1111, 2016
15. **Marti HP**, Jeffs A, Scherer A, Leader J, Leader C, Bedford C, Walker R. Renal Fibrosis mRNA Classifier: Validation in Experimental Lithium-induced Interstitial Fibrosis in the Rat Kidney. *PLOS One*, Dec 21;11(12):e0168240. doi: 10.1371, 2016.
16. Nowak A, Koch G, Huynh-Do U, Siegenthaler M, **Marti HP**, Pfister M. Disease progression modeling to evaluate the effects of enzyme replacement therapy on kidney function in adult patients with the Classic phenotype of Fabry disease. *Kidney Blood Press Res*, 42(1):1-15, 2017.
17. Landolt L, Eikrem Ø, Strauss P, Scherer A, Lovett DH, Beisland C, Finne K, Osman T, Ibrahim MM, Gausdal G, Ahmed L, Lorens JB, Thiery JP, Tan TZ, Sekulic M, **Marti HP**. Clear Cell Renal Cell Carcinoma is linked to Epithelial-to-Mesenchymal Transition and to Fibrosis. *Physiol Rep*. Jun;5(11). pii: e13305. doi: 10.14814/phy2.13305, 2017.
18. Martin-Gandul C, Stampf S, et al; Swiss Transplant Cohort Study (STCS, **Marti H.P.** listed here). Preventive Strategies Against Cytomegalovirus and Incidence of α -Herpesvirus Infections in Solid Organ Transplant Recipients: A Nationwide Cohort Study. *Am J Transplant*. Jul;17(7):1813-1822, 2017.
19. Paunas T, Finne K, Leh S, **Marti HP**, Mollnes TE, Berven F, Vikse BE. Glomerular abundance of complement proteins characterized by proteomic analysis of laser-captured microdissected glomeruli associates with progressive disease in IgA nephropathy. *Clin Prot*. Aug 14;14:30, doi 10.1186/s12014-017-9165-x, 2017.
20. Xu Q, Junttila S, Scherer A, Giri K, Kivelä O, Skovorodin I, Röning J, Quaggin S, **Marti HP**, Shan J, Samoylenko A. Renal Carcinoma/Kidney Progenitor Cell Chimera Organoid as a Novel Tumorigenesis Gene Discovery Model. *Dis Model Mech*, 10(12):1503-1515, 2017.
21. Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Perrone RD, Koch G, Ouyang J, McQuade RD, Blais JD, Czerwiec FS, Sergeeva O., for the REPRISE Trial Investigators (**Marti HP** listed there) Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease. *New Engl J Med*, Nov 16;377(20):1930-1942, 2017.
22. Strauss Ph, **Marti HP**, Beisland C, Scherer A, Lysne V, Leh S, Flatberg A, Koch E, Beisvag V, Landolt L, Skogstrand T, Eikrem O. Expanding the utilization of formalin-fixed, paraffin-embedded archives: feasibility of miR-seq for disease exploration and biomarker development from biopsies with clear cell renal cell carcinoma. *Int J Mol Sci*, Mar 10;19(3), 2018.
23. Cusini A, Béguelin C, Stampf S et al. Clostridium difficile infection is associated with graft loss in solid organ transplant recipients; Swiss Transplant Cohort Study (STCS, **Marti H.P.** listed here). *Am J Transplant*. 2018 Jul;18(7):1745-1754.
24. Tariq A, Mansoor MA, **Marti HP**, Jonsson G, Slettan A, Weeraman P, Apeland T, Systemic redox biomarkers and their relationship to prognostic risk markers in autosomal dominant polycystic kidney disease and IgA nephropathy. *Clinical Biochemistry*, Apr 12, pii:S0009-9120(17)31049-4, 2018.
25. Eikrem O, Walther TC, Flatberg A, Beisvag V, Strauss Ph, Farstad M, Beisland C, Koch E, Mueller TF, and **Marti H.P.** Fine Needle Aspirates of Kidneys: a promising tool for RNA sequencing in native and

- transplanted kidneys. *BMC Nephrol*, Sep 5;19(1):221, 2018. doi: 10.1186/s12882-018-1012-4.
26. Dierkes J, Dahl H, Lervaag Welland N, Sandnes K, Sæle K, Sekse I, **Marti HP**. High rates of central obesity and sarcopenia in CKD irrespective of renal replacement therapy – an observational cross-sectional study. *BMC Nephrol*, Oct 11;19(1):259, 2018. doi: 10.1186/s12882-018-1055-6.
 27. Ruggajo P, Leh S, Svarstad E, **Marti HP** Vikse BE. Low Birth Weight Associates with Glomerular Area in Young Male IgA Nephropathy Patients. *BMC Nephrol*, 19:287, 2018. doi: 10.1186/s12882-018-1070-7.
 28. Hodneland E, Keilegavlen E, Hanson EA, Andersen E, Monssen JA, Rørvik J, Leh S, **Marti HP**, Lundervold A, Svarstad E, and Nordbotten J. In vivo detection of chronic kidney disease using tissue deformation fields from dynamic MR imaging. *IEEE Trans Biomed Eng*, 2019 Jun;66(6):1779-1790.
 29. Koch, Finne K, Eikrem O, Landolt L, Beisland C, Leh S, Delaleu N, Granly M, Vikse BE, Osman T, Scherer A, **Marti HP**. Transcriptome-proteome integration of archival human renal cell carcinoma biopsies enable identification of molecular mechanisms. *Am J Physiol – Renal Physiol*, 2019 May 1;316(5):F1053-F1067. doi: 10.1152/ajprenal.00424.2018.
 30. Landolt L, Furriol J, Babickova J, Ahmed L, Eikrem O, Skogstrand T, Scherer A, Suliman S, Leh S, Lorens JB, Gausdal G, **Marti HP**, Osman T. AXL targeting reduces fibrosis development in experimental unilateral ureteral obstruction. *Physiol Rep*, 2019 May;7(10):e14091. doi: 10.14814/phy2.14091.
 31. Paunas FTI, Finne K, Leh S, Osman TA, **Marti HP**, berven F, Viske BE. Characterization of glomerular extracellular matrix in IgA nephropathy by proteomic analysis of laser-captured microdissected glomeruli. *BMC Nephrol*. 2019 Nov 14;20(1):410. doi: 10.1186/s12882-019-1598-1.
 32. Gjerde A, Lillås BS, **Marti HP**, Reisæter AV, Vikse BE. Intrauterine growth restriction, preterm birth and risk of end-stage renal disease during the first 50 years of life. *Nephrol Dial Transpl*, 1–7, 2020. doi: 10.1093/ndt/gfaa001
 33. Circulating inflammation-related factors are correlated with systemic redox status in IgA nephropathy; a case-control study. Apeland T, Mansoor MA, Furriol J, Ushakova A, Jonsson G, Stangeland K, **Marti HP**. *Free Radic Biol Med*, in press, 2020

Reviews

1. **Marti HP**, Dørje Ch, Strøm E. Bedeutung und Management der Rezidive von Glomerulonephritiden im Nierentransplantat. *Ther Umsch*, 72(3):199-206, 2015.
2. Landolt L, Strauss Ph, **Marti HP**, Eikrem O. Next generation sequencing: a tool for this generation of nephrologists. *EMJ Nephrol*, April:1.2., 2016.
3. Căpușă C, Busuioc RM, Pană N, Florescu C, **Marti HP**, Leh S. Kidney biopsy in nephrology practice. *Medical Connections*, 11(4):29-36, 2016.
4. Capusa C, Mehedinti AM, Leh S, **Marti HP**. Nephropathology – A cornerstone for the understanding and recent advances in glomerular diseases. *BANTAO Journal*, 14(2):60-63, 2016
5. **Marti HP**. Leicht erhöhte Nierenwerte: Von Bedeutung? *Primary and Hospital Care*, 17(13):254-256, 2017.
6. Eikrem O, Skrunes R, Tøndel C, Leh S, Houge G, Svarstad E, **Marti HP**. Pathomechanism of renal Fabry disease. *Cell Tissue Res*, Jul;369(1):53-62. 2017.
7. Eikrem O, **Marti HP**. Klarcellet nyrekarsinom er knyttet til epitelial-til- mesenkymal overgang (EMT) og til fibrose. *BestPractice Onkologi/Hematologi*, 36: 4. April 2018.
8. Rondeau R, Luychx VA, Anders HJ, Eckardt KU, Florquin S, **Marti HP**, Ølgaard K, Harden P. The burden of kidney disease in Western Europe. *Kidney Int*, May;95(5):1037-1040, 2019.
9. **Marti HP**, Serebruany V, Atar D. Challenging anticoagulation in advanced renal failure (editorial comment). *Am J Med*. 2019 Jul 26. pii: S0002-9343(19)30574-1. doi: 10.1016/j.amjmed.2019.07.002. [Epub ahead of print]
10. Svarstad E, **Marti HP**. The changing landscape of Fabry disease (invited review). *Clin J Am Soc Nephrol*, volume 15, April 2020; doi: <https://doi.org/10.2215/CJN.09480819>

Latest Case Report

1. Haaskjold YL, Drotningvik A, Leh S, **Marti HP**, Svarstad E. Renal failure due to excessive intake of almonds in the absence of Oxalobacter Formigenes. *Am J Med*. 128(12):e29-30, 2015.

Latest Book Chapter

1. **Marti HP**. How the structure of a transplant center can influence pharmacotherapy. Pharmacotherapy after Transplantation, Transplantologia praktyczna t.7: Chapter 1, 1-8, 2015. ISBN: 978-83-01-18256-4.

Presentations at Conferences

- European Society of Hypertension (ESH), Annual Meeting, Milano, Italy, 2019 (*oral abstract*)
- Cutting Edge in Nephrology Conference, Astellas, Copenhagen, DK, 2019 (*invited lecture*)
- American Society of Nephrology, Annual Meeting 2018 (*oral abstract presentation*)
- 3rd and 4th Pan-Hellenic Congress on Continuing Education in Internal Medicine, Internal Medicine Society of Greece, Thessaloniki, Greece, 2017 and 2018 (*invited lectures*)
- Xth National Congress of Nephrology, Bucharest, Romania, 2017 (*invited lecture*)
- Meeting MAYO Clinic - Norwegian Society of Nephrology, Trondheim 2016 and 2019 (*invited lectures*)
- Course in Nephropathology, Carol Davila University, Bucharest, 2016 (*invited lecture*)
- Bergen Spring Meeting of Nephrology, Bergen, Norway, 2014, 2015 and 2017 (*lectures*)
- Practical Transplantology, Medical University of Warsaw, Poland, 2015 (*invited lecture*)
- Congress of the Nordic Society of Nephrology, Stavanger, Norway, 2015 (*invited lecture*)
- Swiss Society of Nephrology, Annual Meetings, 2014-2018 (*several oral presentations*)

Major contributions to the early careers

- Silke Roedder had moved from my lab after her PhD to become a successful postdoctoral fellow at the renowned Sarwal lab at UCSF (USA) <https://sarwallab.surgery.ucsf.edu/>
- Jana Babickova, postdoc fellow in my laboratory, with MSCA Fellowship (3 years) to work with Agnes Fogo, Dept. of Pathology, Vanderbilt University, Nashville, TN, USA, 2019-2021.



Bergen 07th May 2020

Hans-Peter Marti